Skip to content
DataLookout
Menu

ATACNCT05334940

Atopy Network - Comprehensive Allergy Centers: Medical Care of Patients With Moderate to Severe Allergic Diseases

StatusRecruiting
PhaseNot specified
Primary completion (estimated)

At risk: Primary completion moved 2 years 4 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 5 versions: 5 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary and study completion pushed from Aug 31, 2025 to Dec 31, 2027
    • Eligibility criteria expanded, about 6 words
    • Trial status changed: Unknown → Recruiting
    • Secondary endpoints: details revised at 7 of 11 entries
  2. Minor Changed Registry marked status Unknown; last known: Recruiting
  3. Minor Trial status: Recruiting to Unknownv4
  4. Notable Start date changed from estimate of Sep 1, 2022 to Dec 8, 2022v3
  5. Notable Start date: May 1, 2022 to Sep 1, 2022
    • Primary and study completion dates: Apr 1, 2025 to Aug 31, 2025
    v2
  6. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Comorbidity Food Allergy
Timeframe: 3 years
Comorbidity Atopic Dermatitis
Timeframe: 3 years
Comorbidity Bronchial Asthma
Timeframe: 3 years
Comorbidity Chronic rhinosinusitis with nasal polyps
Timeframe: 3 years
Comorbidity Chronic Spontaneous Urticaria
Timeframe: 3 years
Comorbidity Eosinophilic Esophagitis
Timeframe: 3 years
Comorbidity Allergic Rhinitis
Timeframe: 3 years

Secondary (11)

Food Allergy Severity
Atopic Dermatitis Severity
Allergic Rhinitis Severity
Bronchial Asthma Severity FVC
Bronchial Asthma Severity FEV1
Show 6 moreShow less
Bronchial Asthma Severity FEF25-75
Chronic Spontaneous Urticaria LQ (CUQ2oL)
Chronic Spontaneous Urticaria Severity (AECT)
Chronic Spontaneous Urticaria Severity (UAS7)
Eosinophilic Esophagitis Severity and/or LQ
Chronic Rhinosinusitis with Nasal Polyposis Severity

Arms and interventions

Atopic disorders

Patients with at least 2 atopic disorders who are eligible for systemic therapy with biologics

Other: not applicable, observational study

Sites

1 site in 1 country

  • Charité - Universitätsmedizin BerlinBerlin, Germany